New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT02326974
First seen Apr 23, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This study tests two targeted drugs, T-DM1 and pertuzumab, given before surgery to people with early-stage HER2-positive breast cancer. The goal is to see if this combination can completely eliminate cancer cells in the breast, potentially reducing the need for more aggressive treatments. The trial involves 164 participants with stage II or III breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Tennessee Oncology/Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.